Recent Company News

• 07:07 AM ET Nov 24, 2025
  

  BioLineRx reports Q3 EPS ($0.00) vs FactSet $0.00 [1 est] (1.90a, 0.00)

• 07:00 AM ET Nov 24, 2025
  

  BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

• 07:01 AM ET Nov 18, 2025
  

  BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

• 07:02 AM ET Nov 17, 2025
  

  BioLineRx announces receipt of USPTO notice of allowance for key patent covering GLIX1 for treating a Broad range of cancer types (1.80a, -0.10)

• 07:00 AM ET Nov 17, 2025
  

  BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

• 07:08 AM ET Sep 29, 2025
  

  BioLineRx and Hemispherian announce JV to develop GLIX1, targeting DNA damage response in glioblastoma and other cancers (2.10a, 0.00)

• 07:08 AM ET Aug 14, 2025
  

  BioLineRx reports Q2 EPS ($0.00) vs FactSet $0.00 [3 est, ($0.00)-0.00] (2.20a, +0.10)

• 08:53 AM ET May 30, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:37 AM ET May 30, 2025
  

  BioLineRx upgraded to buy from hold at Jones ($3.79, 0.00)

• 07:04 AM ET May 30, 2025
  

  BioLineRx announces new pilot phase data from Phase 2 combination trial of motixafortide in first line PDAC to be presented at ASCO (2.20a, 0.00)